PRETOMANID: New Drug for Drug-Resistant TB

Treating drug-resistant tuberculosis — multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) — got a shot in the arm on August 14 when the U.S. Food & Drug Administration (FDA) approved a new drug Pretomanid. Pretomanid is only the third new anti-TB drug approved for use by FDA in more than 40 years.

TB Burden

  • Burden in the World: As per World Health Organisation’s Global Tuberculosis Report 2018, an estimated 4.5 lakh people across the world have MDR-TB and nearly 37,500 people have XDR-TB. India has 24% of MDR-TB cases in the world. By the end of 2017, XDR-TB had ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy October 2019 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content

Current Affairs In Focus